Abbott Laboratories (NYSE:ABT) Price Target Cut to $115.00 by Analysts at Raymond James Financial

Abbott Laboratories (NYSE:ABT) had its price target lowered by stock analysts at Raymond James Financial from $130.00 to $115.00 in a report released on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the healthcare product maker’s stock. Raymond James Financial’s price objective would indicate a potential upside of 20.76% from the stock’s current price.

Several other equities analysts have also recently commented on ABT. TD Cowen reduced their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research note on Friday. The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating for the company in a research report on Wednesday, April 8th. Sanford C. Bernstein lowered their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Mizuho cut their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research note on Friday. Finally, Piper Sandler dropped their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $121.00.

Abbott Laboratories Trading Down 0.3%

NYSE ABT opened at $95.23 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 52 week low of $93.92 and a 52 week high of $139.06. The firm has a 50 day moving average of $108.17 and a two-hundred day moving average of $119.01. The stock has a market capitalization of $165.85 billion, a PE ratio of 25.57, a price-to-earnings-growth ratio of 1.62 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Insider Activity

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares of the company’s stock, valued at $12,053,953.78. This represents a 0.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 3,055 shares of company stock worth $353,097. Corporate insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On Abbott Laboratories

Large investors have recently made changes to their positions in the stock. Gemmer Asset Management LLC raised its position in Abbott Laboratories by 2.9% during the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after acquiring an additional 78 shares in the last quarter. Global Financial Private Client LLC grew its holdings in Abbott Laboratories by 3.3% during the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after purchasing an additional 79 shares during the period. Citizens & Northern Corp raised its stake in Abbott Laboratories by 0.4% in the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock valued at $2,930,000 after buying an additional 79 shares during the period. American National Bank of Texas boosted its stake in shares of Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after acquiring an additional 79 shares during the period. Finally, Nia Impact Advisors LLC increased its holdings in shares of Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Q1 beat on both EPS ($1.15 vs. $1.14 est.) and revenue ($11.16B vs. $10.99B), driven by medical devices and the newly acquired cancer diagnostics business — confirms underlying growth momentum. Reuters: Abbott first-quarter results beat
• Positive Sentiment: BTIG reaffirmed a Buy and set a $131 price target (?+38% upside vs. current price), signaling some analysts view the acquisition and growth trajectory as accretive over time. TickerReport: BTIG Reaffirms Buy
• Neutral Sentiment: Abbott officially updated FY2026 guidance to $5.38–$5.58 (includes ~$0.20 dilution from Exact Sciences) and Q2 guidance to $1.25–$1.31, which is below prior consensus — investors must weigh near-term EPS hit vs. long-term oncology exposure. PR Newswire: Abbott Reports Q1, Updates Guidance
• Neutral Sentiment: Analyst coverage remains generally bullish (Buy ratings from multiple firms and mid-$120s PTs from some outlets like 24/7 Wall St.), keeping a positive baseline for longer-term holders. 24/7 Wall St.: ABT price prediction
• Negative Sentiment: Management’s lowered guidance and the ~$0.20 EPS dilution tied to the Exact Sciences buyout spurred selling pressure; margin compression and a weak nutrition segment were flagged on the call. WSJ: Abbott cuts outlook
• Negative Sentiment: Several firms trimmed price targets after the print—Bank of America and Stifel lowered PTs (to $120) even while keeping Buy ratings, reflecting reduced near-term upside expectations. Benzinga: Analyst price target changes
• Negative Sentiment: Shares reacted negatively after the print as investors prioritized the guidance cut and merger dilution over the modest beat; short-term volatility and ETF flows were noted by several outlets. Motley Fool: Why ABT tumbled

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.